Why the study?
Does prior antiplatelet therapy affect the risk of symptomatic intracerebral hemorrhage and functional outcome in patients with acute ischemic stroke receiving intravenous thrombolysis?
Population
301 consecutive patients with acute ischemic stroke undergoing intravenous thrombolysis with tissue…
Comparison
Prior use of antiplatelet drugs before… vs No prior use of antiplatelet drugs before…
Design
Cohort
Follow-up
3 months
Authors
Loading...
Supports net functional benefit despite sICH risk in observational data; leaves open whether prior antiplatelet therapy should influence thrombolysis decisions.
Does prior antiplatelet therapy affect the risk of symptomatic intracerebral hemorrhage and functional outcome in patients with acute ischemic stroke receiving intravenous thrombolysis?
Despite increasing the risk of symptomatic intracerebral hemorrhage, prior antiplatelet therapy is associated with a net functional benefit in acute ischemic stroke patients receiving intravenous thrombolysis.
Uyttenboogaart et al. (2008) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: